Ammonium Sulfate Addition Reduces the Need for Guanidinium Isothiocyanate in the Denaturing Transport Medium Used for SARS-COV-2 RNA Detection

1 Ge Liu¹, Jiaoyan Jia², Jianfeng Zhong², Hanfang Jiang³, Yongqi Yang², Xiujing Lu⁴*, Zhendan

2 He¹*, Qinchang Zhu^{1,2}*

3

- ⁴ ¹College of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, PR China
- 5 ²School of Pharmaceutical Sciences, Shenzhen University, Shenzhen, 518060, PR China
- ⁶ ³Clinical Laboratory, Shenzhen Children's Hospital, Shenzhen, 518038, PR China

⁷ ⁴GBCBIO Technologies Inc., Guangzhou, 511434, PR China

8

9 * Correspondence:

- 10 Xiujing Lu: Email: lu3002@163.com; Zhendan He: Email: hezhendan@sztu.edu.cn;
- 11 Qinchang Zhu: Email: zhuqc@szu.edu.cn
- 12
- 13

14 Abstract

15 Rapid identification of SARS-CoV-2 infected individuals through viral RNA detection followed by

16 effective personal isolation remains the most effective way to prevent the spread of this virus. Large-

17 scale RNA detection involves mass specimen collection and transportation. For biosafety reasons,

18 denaturing viral transport medium has been extensively used during the pandemic. But the high

19 concentrations of guanidinium isothiocyanate (GITC) in such media have raised issues around

- 20 sufficient GITC supply and laboratory safety. Here, we tested whether supplementing media
- containing low concentrations of GITC with ammonium sulfate (AS) would affect the throat-swab
 detection of SARS-CoV-2 pseudovirus or a viral inactivation assay targeting both enveloped and
- detection of SARS-CoV-2 pseudovirus or a viral inactivation assay targeting both enveloped and non-enveloped viruses. Adding AS to the denaturing transport media reduced the need for high levels
- of GITC and improved SARS-COV-2 RNA detection without compromising virus inactivation.
- 25

Keywords: COVID-19, RNA detection, denaturing transport media, guanidinium isothiocyanate,

- ammonium sulfate
- 28
- 29
- _,
- 30
- 31

32

33 1 Introduction

34 The ongoing COVID-19 pandemic has resulted in more than 422 million infections and 5.8 million 35 deaths worldwide since its emergence in late 2019 [1, 2]. It appears to have now entered a new wave 36 of infection sparking by the heavily mutated Omicron variant [3]. Although several vaccines (e.g., 37 mRNA vaccines, inactivated vaccines, and viral vector vaccines) have been conditionally approved 38 in some countries [4, 5] and various antiviral agents are in various stages of clinical trial [6, 7], there 39 is currently no effective way to control the COVID-19 pandemic. Before all susceptible populations 40 are fully protected, it remains extremely important to deal with the pandemic by controlling the 41 infection sources and blocking the transmission routes, both of which rely on rapidly 42 identifying SARS-CoV-2 infected individuals and isolating them from the population. Nucleic acid-43 based methods are the fastest methods for detecting SARS-CoV-2, especially in the early infection 44 stages [8]. Such methods have played irreplaceable roles in the mass screening for SARS-CoV-45 2 infection. Large-scale nucleic acid testing has been implemented following local case reports where 46 possible community transmission is indicated and this approach has supported China's sustained 47 containment of COVID-19 [9]. Wuhan (Hubei Province) performed city-wide mass screening using 48 reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) testing for nearly 10 million 49 people over a 10-day period [10], and Qingdao (Shandong Province) tested 10.9 million people for

50 SARS-CoV-2 RNA in 5 days [11].

51 Large-scale nucleic acid testing involves large-scale specimen collection and transportation. 52 Nasopharyngeal swabs and throat swabs are usually used in the specimen collection for SARS-CoV-53 2 RT-PCR testing [8]. After collection, specimens are generally preserved and transported in 54 nondenaturing or denaturing media. Nondenaturing media, such as conventional viral transport 55 medium and Amies transport medium, mainly contain saline buffer and antibiotics [12-14]. 56 Nondenaturing media are used to maintain the integrity and infectivity of the viruses in the specimen. 57 Therefore, nondenaturing media are used to detect viral nucleic acids and antigens or for culture-58 based viral detection. However, laboratory personnel risk infection when handling infectious 59 specimens during the testing process, especially during large-scale testing [15]. Denaturing transport 60 media usually contain guanidinium isothiocyanate (GITC) or other virus-inactivating denaturants, 61 which is why they are only suitable for nucleic acid detection. One advantage of denaturing transport 62 medium is its potential to reduce the risk of infection of laboratory personnel and improve SARS-63 CoV-2 RNA detection [16-18]. Both denaturing and nondenaturing viral transport media are widely used [13, 17, 19], and the former are recommended in China for large-scale nucleic acid testing [20]. 64 65 Although various commercially available and in-house denaturing viral transport media exist, there 66 are no uniform formulation standards. The core component of denaturing viral transport media is 67 usually GITC, whose concentrations are mostly between 30%–50% (2.5M–4.2M) [17]. GITC is a 68 chaotropic agent with a strong protein denaturing function. It is commonly used as a nucleic 69 acid protector during RNA and DNA extraction because it denatures RNases and DNases. GITC is 70 also used to deactivate many viruses including SARS-CoV-2 [17, 21, 22].

However, with the growing demand for denaturing viral transport media in large-scale nucleic
acid testing, a GITC supply shortage occurred and its price doubled in early 2021 in China.
Therefore, optimizing the formulation by reducing the GITC content may be a way to help meet the
demand for SARS-CoV-2 nucleic acid screening and reduce the testing costs. Ammonium sulfate
(AS) is a low-cost inorganic salt with high water solubility from its ionic nature. It is often used for
protein precipitation and purification in the laboratory. High-concentration AS is also used to

medRxiv preprint doi: https://doi.org/10.1101/2022.02.28.22271591; this version posted March 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission of the state of the st

enhance RNA stability in tissue samples [23, 24]. Here, we report that reducing the amount of GITC

in denaturing viral transport media while adding AS to them can improve the sensitivity of SARS-

79 CoV-2 RNA detection without affecting the virus inactivation effect.

80 2 Materials and methods

81 **2.1 Cells and viruses**

82 Vero cells (ATCC, CCL-81) were cultured in Dulbecco's modified Eagle's medium (Gibco, NY,

83 USA) supplemented with 10% (v/v) fetal calf serum. SARS-CoV-2 pseudovirus (FNV-2019-nCoV-

abEN, >10⁸ copies/mL) was purchased from Fubio Biological Technology Co., Ltd. (Hangzhou,

85 China). Herpes simplex virus type 1 (HSV-1, VR-733) originated from the American Type Culture

86 Collection. Enterovirus 71 (EV71, C4 strain) was kindly provided by Dr Tao Peng, Guangzhou

87 Medical University, China. Both HSV-1 and EV71 were propagated and titred in Vero cells. SARS-

88 CoV-2 pseudovirus was used directly.

89 2.2 Denaturing solutions

- 90 Modified Primestore MTM (Molecular Transport Medium), which we used as a reference medium,
- 91 contains 3M GITC, 25 mM sodium citrate, 0.5% SLS (sodium lauryl sulfate) and 20 mM
- 92 ethylenediaminetetraacetic acid. Basing on the modified Primestore MTM, we prepared the

93 denaturing transport medium with various GITC concentrations and/or AS as indicated.

94 2.3 SARS-CoV-2 RNA detection

- 95 A throat swab sample from a healthy person was collected in 4 mL saline, and the 100 μL of SARS-
- 96 CoV-2 pseudovirus (>10⁷ copies) we added to the sample was mixed in by vortexing. Next, 200 μ L
- 97 of the SARS-CoV-2 pseudovirus-containing throat swab sample was added to 1 mL of each
- denaturing solution we prepared or to PBS. The solutions were kept at room temperature (RT) or
- 99 37°C , and RNA was extracted from them using the Virus DNA/RNA Kit (GBCBIO) after incubation
- 100 for 24 h, 72 h, 120 h or 5 d. RT qPCR detection of SARS-CoV-2 RNA was performed in 20-μL
- 101 reactions. The BeyoFast[™] Probe One-Step qRT-PCR Kit (Beyotime) and primer and probe
- sequences targeting the ORF1ab gene and N gene were used in accordance with the protocols for
- 103 COVID-19 Prevention and Control Guidelines (Seventh Version) issued by China's National Health
- 104 Commission. The cycle threshold (Ct value) for each sample was recorded and used for cross-sample
- 105 comparisons. Graphs and statistical analyses (multiple t tests) were prepared with GraphPad Prism
- 106 8.0.2 (GraphPad Software, Inc, La Jolla, CA, United States). Statistical significance determined using
- 107 the Holm-Sidak method, with alpha of 0.01.

108 2.4 Virus inactivation assay

- 109 The viral inactivation abilities of the denaturing solutions containing different GITC concentrations
- 110 and/or AS were investigated using a plaque reduction assay. HSV-1 virus (100 μ L, 4.135 \times 10⁸
- 111 plaque forming units (PFUs)/mL) or EV71 virus (5×10^7 PFUs/mL) was added to 0.9 mL of each
- denaturing solution, and each solution was mixed and incubated for 1 h at RT. After incubation, each
- 113 mixture was serially diluted and filtered through Millex-GP 0.22 µm membrane filters (Millipore)
- and finally used in a plaque reduction assay using previously described procedures [25, 26].

115 **3 Results and discussion**

116 **3.1 Effects of the test solutions on SARS-CoV-2 RNA detection**

117 To evaluate the effect of adding AS to denaturing transport media on SARS-CoV-2 RNA detection, a

- 118 modified commercial denaturing transport medium containing 3M GITC was used as the basic
- 119 formula and reference reagent in the experiments. To mimic the sampling of SARS-CoV-2, a throat
- 120 swab sample from a healthy person was mixed with SARS-CoV-2 pseudovirus. It was then placed
- 121 into denaturing media containing different concentrations of GITC and AS and incubated at room
- 122 temperature or 37°C for 24 h, 72 h, 120 h or 5 d as indicated. After RNA extraction, qRT-PCR on the
- 123 SARS-CoV-2 ORF1ab and N genes was performed and comparatively analysed.

124 The results showed that reducing the GITC concentrations increased the Ct values, but adding 125 1M AS to the transport media reduced the Ct values of the ORF1ab gene and the N gene irrespective 126 of the 24-h, 72-h or 120-h incubation period (Fig. 1A and 1B). A further assay on the samples

- incubated at RT or 37°C for 5 days revealed that adding 1M AS to transport media containing lower
- 128 GITC concentrations significantly reduced the Ct values when compared with PBS or the transport
- medium containing 3M GITC (p<0.01) (Fig. 1C). A clear dose-dependent effect was observed when
- 130 AS was added to each transport medium containing a fixed GITC concentration (Fig. 1D). Because
- 131 lower Ct values indicate higher qRT-PCR detection efficiency, these results clearly suggest that
- adding AS to the transport media can reduce the amount of GITC required for sample denaturation
- 133 and increase the detection efficiency for SARS-CoV-2 RNA.

134 GITC is commonly used at high concentrations in denaturing viral transport media [17, 21].

- 135 However, the sharp increase in demand for large-scale nucleic acid testing is causing a shortage of
- 136 GITC during the ongoing COVID-19 pandemic. Another issue is that the high GITC concentrations 137 used in the viral testing platforms can react with bleach (sodium hypochlorite) to produce harmful
- used in the viral testing platforms can react with bleach (sodium hypochlorite) to produce harmfulcyanide gas [27]. Therefore, reducing the GITC concentrations in transport media is worthwhile.
- However, we found that simply reducing its concentration in transport media is worthwhile
- 140 detection efficiency towards SARS-CoV-2 RNA (Fig. 1A and 1B). Here, we showed that adding AS
- 141 to the transport media not only recovered but also improved the detection efficiency when low
- 142 concentrations of GITC were present. The use of AS to precipitate proteins out of solution is known,
- and AS have been reported to suppress more than 90% of RNase A activity [28, 29]. Therefore, the
- improved RNA detection efficiency observed in this study possibly resulted from AS-induced
- 145 denaturation of the RNase A protein, but further research is needed to confirm it.

146 **3.2 Inactivation effects on enveloped and non-enveloped viruses**

- 147 To compare the virus inactivation effects of denaturing transport media containing low
- 148 concentrations of GITC and 1M AS with a commonly used denaturing transport medium, a plaque
- reduction assay designed for enveloped and non-enveloped viruses was performed. SARS-CoV-2 is
- an enveloped virus. However, the biosafety hazards relating to conducting experiments with a live
- 151 SARS-CoV-2 virus caused us to use a common enveloped virus, HSV-1, to evaluate the inactivation
- effect of various transport media against this virus. We also tested EV71, a non-enveloped virus with
- a typical icosahedral capsid structure. After subjecting the viruses to various denaturing solutions at
- 154 RT for 1 h, each virus was subjected to a plaque reduction assay.

The results showed that a common denaturing viral transport medium containing 3M GITC completely inactivated both HSV-1 and EV71 (Fig. 2A and 2B). No difference was observed in HSV-1 inactivation when 1M AS was added to the media even when the GITC concentrations were reduced to 0.1M (Fig. 2A). In the EV71 inactivation experiments, the effect of supplementing the

- transport media with 0.5 M GITC plus 1M AS was equal to that where 3M GITC was present, and
- 160 EV71 was completely inactivated (Fig 2B). These results suggest that decreasing the GITC

- 161 concentrations but adding AS to the transport media did not affect the virus inactivation effect when
- 162 compared with general denaturing transport medium containing GITC at high concentration.

163 4 Conclusions

- 164 Faced with the ongoing global COVID-19 pandemic, we sought a safer, low-cost denaturing viral
- transport medium for preserving SARS-CoV-2 RNA without compromising the effectiveness of viral
- 166 detection. Based on the components of the modified commercial transport medium we used as a
- 167 reference reagent, we reduced the GITC concentrations in the media, added AS, and obtained a new
- 168 formula. We tested the different transport media by detecting SARS-CoV-2 pseudovirus in a throat
- swab sample and via a viral inactivation assay targeting both enveloped and non-enveloped viruses.
- We found that adding AS to the denaturing transport media reduced the use of GITC, improved
- 171 SARS-COV-2 RNA detection, and did not compromise the virus inactivation effect of the media.
- 172 These findings suggest that AS is a potential component that when added to denaturing transport
- 173 medium may reduce the cost and improve the detection efficiency towards SARS-COV-2 RNA.

174 **Conflict of Interest**

- 175 Author Xiujing Lu was employed by GBCBIO Technologies Inc.. The remaining authors declare that
- the research was conducted in the absence of any commercial or financial relationships that could be
- 177 construed as a potential conflict of interest.

178 Author Contributions

- 179 LG conceived, planned the experiments and wrote the manuscript. JJY, ZJF and YYQ carried out the
- 180 experiment. JHF analyzed the data and reviewed the manuscript. LXJ, HZD and ZQC conceived the
- 181 original idea, acquired financial support and supervised the project.

182 Funding

- 183 This project was funded by the Science and Technology Program of Guangdong Province
- 184 (2018A030313252), the Shenzhen Science and Technology Project (JCYJ20190808122605563), the
- 185 Shenzhen Peacock Plan and the Fundamental Research Funds for Shenzhen Technology University.

186 Acknowledgments

- 187 We thank Professor Tao Peng of Guangzhou Medical University for providing enterovirus 71. We
- also thank Dr. Sandra Cheesman for editing the language of a draft of this manuscript.
- 189

190 **References**

- Wang, C., et al., A novel coronavirus outbreak of global health concern. Lancet, 2020. 395(10223): p. 470-473.
- 193 2. WHO, Weekly epidemiological update on COVID-19 22-February-2022.
 194 https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-february 195 2022, 2022
- 196 3. Callaway, E., *Heavily mutated Omicron variant puts scientists on alert.* Nature, 2021. 600(7887): p. 21.
- 198 4. Li, Y., et al., A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS

199		Central Science, 2021. 7(4): p. 512-533.
200	5.	Sharma, O., et al., A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
201		Front Immunol, 2020. 11: p. 585354.
202	6.	Espano, E., et al., COVID-19 Antiviral and Treatment Candidates: Current Status. Immune Netw,
203		2021. 21 (1): p. e7.
204	7.	Simsek Yavuz, S. and S. Unal, Antiviral treatment of COVID-19. Turk J Med Sci, 2020. 50(SI-1): p.
205		611-619.
206	8.	Tsang, N.N.Y., et al., Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-
207		PCR testing: a systematic review and meta-analysis. The Lancet Infectious Diseases.
208	9.	Li, Z., et al., Comprehensive large-scale nucleic acid-testing strategies support China's sustained
209		containment of COVID-19. Nature Medicine, 2021. 27(5): p. 740-742.
210	10.	Cao, S., et al., Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of
211		Wuhan, China. Nature Communications, 2020. 11(1): p. 5917.
212	11.	Xing, Y., et al., Rapid Response to an Outbreak in Qingdao, China. N Engl J Med, 2020. 383(23): p.
213		e129.
214	12.	Smith, K.P., et al., Large-Scale, In-House Production of Viral Transport Media To Support SARS-CoV-
215		2 PCR Testing in a Multihospital Health Care Network during the COVID-19 Pandemic. J Clin
216		Microbiol, 2020. 58 (8).
217	13.	Penrod, Y., D. Garcia, and S.T. Dunn, Evaluation of transport media for laboratory detection of SARS-
218		CoV-2 in upper respiratory tract swab specimens. J Med Virol, 2021. 93(5): p. 2774-2781.
219	14.	Johnson, F.B., Transport of viral specimens. Clin Microbiol Rev, 1990. 3(2): p. 120-31.
220	15.	Karthik, K., et al., Biosafety Concerns During the Collection, Transportation, and Processing of
221		COVID-19 Samples for Diagnosis. Arch Med Res, 2020. 51(7): p. 623-630.
222	16.	Carvalho, A.F., et al., The use of denaturing solution as collection and transport media to improve
223		SARS-CoV-2 RNA detection and reduce infection of laboratory personnel. Brazilian Journal of
224		Microbiology, 2021. 52 (2): p. 531-539.
225	17.	Welch, S.R., et al., Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic
226		Acid Extraction Reagents, Detergents, and Fixatives. Journal of clinical microbiology, 2020. 58(11): p.
227		e01713-20.
228	18.	Erster, O., et al., Improved sensitivity, safety, and rapidity of COVID-19 tests by replacing viral
229		storage solution with lysis buffer. PLoS One, 2021. 16(3): p. e0249149.
230	19.	van Bockel, D., et al., Evaluation of Commercially Available Viral Transport Medium (VTM) for
231		SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing. Viruses, 2020. 12(11).
232	20.	China, N.H.C.o.t.P.s.R.o., SARS-CoV-2 Nucleic Acid Test Workbook for Medical Institutions (Trial
233		Version 2). http://www.nhc.gov.cn/yzygj/s7659/202012/b89bcd0813da41788688eb14787b3c72.shtml,
234		2020.
235	21.	Pastorino, B., et al., Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious
236		<i>Samples</i> . Viruses, 2020. 12 (6).
237	22.	Westhaus, S., et al., Evaluation of stability and inactivation methods of SARS-CoV-2 in context of
238		laboratory settings. bioRxiv, 2020: p. 2020.09.11.292581.
239	23.	Daum, L.T., et al., A clinical specimen collection and transport medium for molecular diagnostic and
240		genomic applications. Epidemiol Infect, 2011. 139(11): p. 1764-73.
241	24.	Mutter, G.L., et al., Comparison of frozen and RNALater solid tissue storage methods for use in RNA
242		expression microarrays. BMC Genomics, 2004. 5(1): p. 88.
243	25.	Zhu, Q.C., Y. Wang, and T. Peng, Herpes simplex virus (HSV) immediate-early (IE) promoter-directed
244		reporter system for the screening of antiherpetics targeting the early stage of HSV infection. J Biomol
245		Screen, 2010. 15 (8): p. 1016-20.
246	26.	Zhu, Q.C., et al., Inhibition of enterovirus 71 replication by chrysosplenetin and penduletin. Eur J
247		Pharm Sci, 2011. 44 (3): p. 392-8.
248	27.	Paik, S. and X. Wu, Measuring toxic gases generated from reaction of guanidine isothiocyanate-
249		containing reagents with bleach. Chemical Health & Safety, 2005. 12(4): p. 33-38.
250	28.	Allewell, N.M. and A. Sama, The effect of ammonium sulfate on the activity of ribonuclease A.
251		Biochim Biophys Acta, 1974. 341 (2): p. 484-8.

- 252 29. ES, L., Methods and reagents for preserving RNA in cell and tissue samples. US Patent, 253 2001(6,204,375).
- 254
- 255
- Figure 1. Effects of ammonium sulfate (AS) addition to denaturing transport media on SARS-CoV-2
- 257 RNA detection. (A) ORF1ab gene detection for various samples in denaturing media or PBS for 24 h,
- 258 72 h and 120 h at room temperature (RT). (B) N gene detection for various samples in denaturing
- 259 media or PBS for 24 h, 72 h and 120 h at RT. (C) ORF1ab gene detection for various samples in
- denaturing media or PBS for 5 d at RT or 37° C.**p<0.01 vs. 3M GITC group. (D) N gene detection
- 261 for various samples in denaturing media across an AS concentration gradient for 72 h at RT.
- ^{**}p<0.01 vs. Control group. GITC: guanidinium isothiocyanate. Samples without GITC and AS are
- the PBS controls.

264

265 Figure 2. Effects of denaturing transport media containing low concentrations of guanidinium

266 isothiocyanate (GITC) and ammonium sulfate supplementation on virus inactivation. (A) Plaque

assay targeting the enveloped HSV-1 virus. (B) Plaque assay targeting the EV71 non-enveloped

virus. Viruses were incubated in PBS or transport media containing the indicated components,

followed by plaque assays on Vero cells. Plaques were visualized by crystal violet staining. Left

270 panels: representative plaques. Right bar charts: virus titres calculated from the plaque assays. Data

271 represent the average \pm SD from three independent experiments.

272





